Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search person

Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma

Posted: Feb 11, 2017
Clinical Trial: Bortezomib or Carfilzomib with Lenalidomide and Dex for Newly Diagnosed Myeloma image

Which combination therapy is best for newly diagnosed myeloma patients? This randomized phase III study compares bortezomib, lenalidomide and dexamethasone (RVd) with carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed patients. Both options are considered "standard of care" treatments for newly diagnosed multiple myeloma. This study is open at 21 different locations in Wisconsin. Click here to learn more: Newly Diagnosed Myeloma Clinical Trial  

Which combination therapy is best for newly diagnosed myeloma patients? This randomized phase III study compares bortezomib, lenalidomide and dexamethasone (RVd) with carfilzomib, lenalidomide and dexamethasone (CRd) in newly diagnosed patients. Both options are considered "standard of care" treatments for newly diagnosed multiple myeloma. This study is open at 21 different locations in Wisconsin. Click here to learn more: Newly Diagnosed Myeloma Clinical Trial  

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.